Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 6868 · ACCESS Through OTC Innovation Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 355h Regulation of certain nonprescription drugs that are marketed without an approved drug application

+32 −12Shown
More for 21 U.S.C. § 355h
Read § 355hOnly this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    by redesignating subsection (q) as subsection (r); and

    The section already has a provision under this letter or number, so it would have two.

  2. Carried out:

    by inserting after subsection (p) the following:(q) Least burdensome means for supporting requests for certain administrative orders.— (1) In general.— For purposes of determining whether a drug is generally recognized as safe and effective under section 201(p)(1) when evaluating a request submitted under subsection (b)(5), …

This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.

§ 355h(o)–(r)

Start of § 355h to (n) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(o)(o) Inapplicability of Paperwork Reduction Act(o) Inapplicability of Paperwork Reduction Act
Chapter 35 of title 44 shall not apply to collections of information made under this section.Chapter 35 of title 44 shall not apply to collections of information made under this section.
(p)(p) Inapplicability of notice and comment rulemaking and other requirements(p) Inapplicability of notice and comment rulemaking and other requirements
The requirements of subsection (b) shall apply with respect to orders issued under this section instead of the requirements of subchapter II of chapter 5 of title 5.The requirements of subsection (b) shall apply with respect to orders issued under this section instead of the requirements of subchapter II of chapter 5 of title 5.
(q)(q) [inserted: Least burdensome means for supporting requests for certain administrative orders.—]
(q)(1)(1) [inserted: In general.—]
[inserted: For purposes of determining whether a drug is generally recognized as safe and effective under section 201(p)(1) when evaluating a request submitted under subsection (b)(5), the Secretary shall apply the least burdensome appropriate means for supporting such a request and satisfying the requirements of this section.]
(q)(2)(2) [inserted: Meeting requests.—]
(q)(2)(A)(A) [inserted: In general.—]
[inserted: In the case of an order requested under subsection (b)(5), and if published reports are insufficient to support the requested findings, the Secretary shall meet with the requestor, if the requestor makes a reasonable written request for the meeting, for the purpose of providing recommendations on the types of evidence necessary, including, if appropriate, the potential design and size of any studies to support a demonstration that the drug is generally recognized as safe and effective.]
(q)(2)(B)(B) [inserted: Preparation and availability of meeting minutes.—]
[inserted: The Secretary shall prepare, and make available to the requestor, the minutes of any such meeting.]
(q)(2)(C)(C) [inserted: Administrative record.—]
[inserted: In the case of any such meeting, the Secretary shall reduce to writing and make a part of the administrative record—]
(q)(2)(C)(i)(i) [inserted: ]
[inserted: any recommendations regarding the parameters of studies under this paragraph that the Secretary provides to the requestor; and]
(q)(2)(C)(ii)(ii) [inserted: ]
[inserted: a summary of the meeting discussion.]
(q)(3)(3) [inserted: Rule of construction.—]
[inserted: Nothing in this subsection shall be construed to alter, supersede, or limit the criteria—]
(q)(3)(A)(A) [inserted: ]
[inserted: for determining under subsection (b)(5)(A) whether a request is sufficiently complete and formatted to permit a substantive review; or]
(q)(3)(B)(B) [inserted: ]
[inserted: for determining whether a drug is generally recognized as safe and effective under section 201(p)(1).]
(r)[struck: (q)] Definitions[inserted: (r)] Definitions
In this section:In this section:
(r)(1)(1) (1)
The term “nonprescription drug” refers to a drug not subject to the requirements of section 353(b)(1) of this title.The term “nonprescription drug” refers to a drug not subject to the requirements of section 353(b)(1) of this title.
(r)(2)(2) (2)
The term “sponsor” refers to any person marketing, manufacturing, or processing a drug that—The term “sponsor” refers to any person marketing, manufacturing, or processing a drug that—
(r)(2)(A)(A) (A)
is listed pursuant to section 360(j) of this title; andis listed pursuant to section 360(j) of this title; and
(r)(2)(B)(B) (B)
is or will be subject to an administrative order under this section of the Food and Drug Administration.is or will be subject to an administrative order under this section of the Food and Drug Administration.
(r)(3)(3) (3)
The term “requestor” refers to any person or group of persons marketing, manufacturing, processing, or developing a drug.The term “requestor” refers to any person or group of persons marketing, manufacturing, processing, or developing a drug.
(r)(r) Evidence and testing standards for active ingredients for topical administration(r) Evidence and testing standards for active ingredients for topical administration
(r)(1)(1) Evidence and testing standards for active ingredients for topical administration(1) Evidence and testing standards for active ingredients for topical administration
The Secretary shall—The Secretary shall—

Rest of § 355h unchanged

Step through the changes